Immaculate therapeutic antibody discovery

Harnessing its antibody discovery platform Symplex, Symphogen has developed a fully integrated approach to discovering and developing next-generation antibody therapeutics.

Sep 12, 2019
0
0
Page of

Symphogen

Symphogen’s strategic priority is to commercialize our powerful research, preclinical and early development platform with the aim of establishing Symphogen as a preferred partner for the discovery and development of highly differentiated antibody therapeutics, either as combination or stand-alone therapies. We will fully utilize the strengths of our technology platform and productive research engine, that have already successfully delivered high quality antibodies with unique functional properties and efficiently brought them to the clinic. Our heritage of identifying and developing combination therapies positions us at the core of future cancer treatments.

No comments yet.